Competing interests
MM
AT received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline and Takeda. MM has received honoraria from Sanofi, Takeda Pharmaceutical Company Ltd., Eli Lilly Japan, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Novo Nordisk Pharma Ltd., Sumitomo Dainippon Pharmaceutical Company and MSD; research funding from Sysmex Corporation and Nissui; and subsidies or donations from Novartis Pharma, Sanofi, and Novo Nordisk Pharma Ltd. KN has received honoraria from MSD, Astella, AstraZeneca, Novartis Pharma, Ono Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Eli Lilly Japan, Boehringer Ingelheim Japan, Takeda Pharmaceutical; Research grant from Asahi Kasei, Astellas, Mitsubishi Tanabe Pharma, Teijin Pharma, Terumo, Boehringer Ingelheim Japan, Eli Lilly and Company, Mochida Pharmaceutical, Fuji Yakuhin; Scholarship from Daiichi Sankyo Healthcare, Teijin Pharma, Medtronic, Bayer Yakuhin. All other authors declare no competing interests.